Power wheelchair — group 2 denied for failing step therapy by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UnitedHealthcare Denied Your Group 2 Power Wheelchair Under "Step Therapy"

Step therapy — sometimes called a "fail-first" requirement — applied to DME means UHC is requiring evidence that you have first tried and failed a less-intensive mobility device before approving a Group 2 power wheelchair. In practice, this often means UHC wants documentation that a manual wheelchair, scooter, or Group 1 power wheelchair was considered or trialed and found clinically inadequate. This denial is procedural: UHC is not saying a Group 2 wheelchair can never be covered, only that it needs evidence of prior steps.

## Why This Denial Is Appealable

Step-therapy requirements can be waived when a lower-level device would be clinically harmful, functionally inadequate, or contraindicated for the patient's condition. Many states have enacted step-therapy override laws, and fully insured plans must comply with those laws. ERISA plans are subject to federal protections. If your prescribing clinician determined that lower-level devices would not meet your clinical needs, that clinical judgment is the basis for an override appeal.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plans) within the deadline on your EOB.
• External review: ACA §2719 entitles you to independent external review after a final internal denial. The reviewer independently assesses whether UHC's step-therapy requirement is clinically appropriate as applied to your case.
• Expedited review: If your current mobility situation poses a health risk, request expedited processing.
• Window: External review requests must generally be filed within four months of a final internal denial.

## Concrete Appeal Steps

1. Request UHC's written step-therapy policy for Group 2 power wheelchairs and the specific criteria for an exception. 2. Have your prescribing physician or physiatrist document in writing why lower-level devices are clinically insufficient for your needs. 3. If you previously trialed a lower-level device, gather records documenting that trial and its outcome. 4. Check whether your state has a step-therapy override law that applies to your plan type. 5. Submit the internal appeal with a physician declaration and supporting clinical records. 6. Request external review if the internal appeal fails.

## Documentation to Gather

• Diagnosis and functional assessment records
• Documentation of any prior mobility device trials, including dates and clinical outcomes
• Physiatrist or therapist evaluation specifically addressing why a Group 2 power wheelchair is necessary and lower-level devices are inadequate
• Prescriber letter invoking the clinical-exception standard under your plan's step-therapy policy

## Criteria-Mapping Structure

Obtain UHC's step-therapy exception criteria from the denial letter or their published DME coverage policy. Address each criterion directly: what is the requirement, and what clinical fact in your chart satisfies it? A structured, criterion-by-criterion response is the format most likely to succeed with both internal reviewers and independent external reviewers.